[go: up one dir, main page]

AR028426A1 - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero - Google Patents

Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero

Info

Publication number
AR028426A1
AR028426A1 ARP010102169A ARP010102169A AR028426A1 AR 028426 A1 AR028426 A1 AR 028426A1 AR P010102169 A ARP010102169 A AR P010102169A AR P010102169 A ARP010102169 A AR P010102169A AR 028426 A1 AR028426 A1 AR 028426A1
Authority
AR
Argentina
Prior art keywords
dysfunsion
mammer
cognitive
diseases
procedure
Prior art date
Application number
ARP010102169A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR028426A1 publication Critical patent/AR028426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP010102169A 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero AR028426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
AR028426A1 true AR028426A1 (es) 2003-05-07

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102169A AR028426A1 (es) 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero

Country Status (16)

Country Link
US (2) US20010036949A1 (es)
EP (1) EP1280554A2 (es)
JP (1) JP2003532670A (es)
AR (1) AR028426A1 (es)
AU (1) AU2001248699A1 (es)
BR (1) BR0110487A (es)
CA (1) CA2409720A1 (es)
EC (1) ECSP014065A (es)
GT (1) GT200100075A (es)
MX (1) MXPA02011051A (es)
PA (1) PA8516701A1 (es)
PE (1) PE20011256A1 (es)
SV (1) SV2002000440A (es)
TN (1) TNSN01068A1 (es)
UY (1) UY26693A1 (es)
WO (1) WO2001085145A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2002085843A2 (en) * 2001-04-20 2002-10-31 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20040006092A1 (en) * 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
CN100549004C (zh) 2003-10-01 2009-10-14 阿得罗公司 螺环杂环衍生物及其应用方法
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
EP1749017A2 (en) * 2004-05-27 2007-02-07 MIGENIX Corp. Compounds and methods for cytoprotection
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007294968A1 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
HK1251980B (en) 2015-05-22 2020-07-10 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
WO2001085145A8 (en) 2001-12-13
MXPA02011051A (es) 2003-03-10
TNSN01068A1 (fr) 2005-11-10
BR0110487A (pt) 2003-04-01
WO2001085145A2 (en) 2001-11-15
US20010036949A1 (en) 2001-11-01
EP1280554A2 (en) 2003-02-05
WO2001085145A3 (en) 2002-06-13
JP2003532670A (ja) 2003-11-05
GT200100075A (es) 2001-12-31
ECSP014065A (es) 2003-01-13
SV2002000440A (es) 2002-10-24
PA8516701A1 (es) 2002-09-17
PE20011256A1 (es) 2001-12-29
CA2409720A1 (en) 2001-11-15
UY26693A1 (es) 2001-12-28
AU2001248699A1 (en) 2001-11-20
US20030130303A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
DE60128441D1 (de) Durchlichtschirm und herstellungsverfahren
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
AU7532601A (en) Materials and methods for the treatment of gastroesophageal reflux disease
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
EP1299337A4 (en) HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60120291D1 (de) Endoskop und Endoskopkapsel
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures

Legal Events

Date Code Title Description
FB Suspension of granting procedure